Elanco Animal Health (ELAN) is back in focus after securing U.S. Department of Agriculture approval for TruCan Ultra Lyme-L4, a 1/2 mL combination vaccine for Lyme disease and leptospirosis in dogs.

The TruCan Ultra Lyme L4 approval lands at a time when Elanco Animal Health’s share price has gained 22.31% over the past month but is still down 3.53% over 90 days, while the 1 year total shareholder return of 73.62% and 3 year total shareholder return of 134.23% point to strong longer term momentum despite a weaker 5 year total shareholder return of 30.34%.

If this kind of product driven story interests you, it can be useful to see what else is moving in related areas by checking out 39 healthcare AI stocks

So with Elanco Animal Health stock up sharply in the past year, yet still trading about 23% below the average analyst price target and at a roughly 33% discount to one intrinsic value estimate, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 18.5% Undervalued

The most followed narrative on Elanco Animal Health currently points to a fair value of $29.79 per share, versus the last close at $24.29, framing a material valuation gap that rests heavily on execution and product adoption.

The successful launch of six potential blockbuster products and exceeding innovation revenue targets for 2024 positions Elanco for strong innovation contributions in 2025, expected to increase innovation revenue, positively influencing earnings.

Operational focus on product launches and divesting non core businesses such as the Aqua division has enabled debt reduction and increased investment capacity, which should improve net margins and financial stability.

Want to see what kind of revenue mix and margin profile would support that higher fair value for Elanco Animal Health? The narrative leans on a specific path for steady top line growth, a swing from losses into positive earnings, and a richer earnings multiple to tie it all together. The exact combination may surprise you.

Result: Fair Value of $29.79 (UNDERVALUED)

However, Elanco Animal Health still faces foreign exchange pressure and higher launch related operating expenses, which could weigh on margins if new products scale more slowly than expected.

Next Steps

Given the mixed signals around Elanco Animal Health, it helps to see the underlying data rather than rely only on headlines. To pressure test the optimism in the story and judge the upside for yourself, start by reviewing the 4 key rewards

Looking for more investment ideas beyond Elanco Animal Health?

If Elanco Animal Health has sharpened your interest in focused opportunities, do not stop here. Broaden your watchlist with a few targeted idea sets that many investors overlook.

• Target resilience with companies that pair steady operations and low volatility by checking out the 68 resilient stocks with low risk scores.
• Hunt for quality at a sensible price by reviewing the 47 high quality undervalued stocks before the crowd starts paying closer attention.
• Spot under followed stories with solid fundamentals by scanning the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.